ExeVir Bio
ActiveSummary
The annual accounts of ExeVir Bio for financial year 2025 show a net loss of 52% of total assets. The 2025 annual accounts show equity of €3.7m and a net result of -€1.9m. Equity is shrinking by about 36% per year and would, assuming unchanged policy, indicatively turn negative around financial year 2026. Its solvency ranks better than 95% of 271 sector peers (NACE 72, financial year 2025). The company has been active since 2020 and the Belgian Official Gazette contains no insolvency or warning signals. The computed 12-month bankruptcy probability is 0.2% (very low).
Articles of association
- Board ruleHow the board is made up, meets and takes decisions.
- “Samenstelling bestuursorgaan, 4” (deed in Dutch)“Waarnemers, niet beschouwd als leden van het bestuursorgaan” (deed in Dutch)“Vergaderingen van het college van bestuurders, schriftelijk” (deed in Dutch)“Volmachten, op iedere door de wet toegelaten wijze” (deed in Dutch)“Besluitvorming, voor de berekening van het vereiste bijzondere aanwezigheids- en stemquorum steeds naar boven zal (moeten) worden afgerond” (deed in Dutch)4 more provisions on this in the deeddeed of 17-02-2026
- Power of attorneyA special mandate allowing someone to perform one or more acts on the company's behalf.
- “Philippe Remels” (deed in Dutch)“Jelle Schuermans” (deed in Dutch)1 more provision on this in the deeddeed of 03-10-2025
Read from the deeds: 12 provisions, deed of 17-02-2026